Results 21 to 30 of about 80 (78)
Рациональная фармакотерапия в кардиологии, 2015 Data on the problem of thromboembolic complications in non-valvular atrial fibrillation are presented. Peculiarities of anticoagulant therapy to prevent thromboembolic complications, the difficulties in drug choice and dosage adjustment are also ...
E. L. Dolgova +2 more
doaj +1 more source
PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST
Рациональная фармакотерапия в кардиологии, 2015 Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base of the efficacy in the prevention of ischemic stroke in patients with atrial fibrillation.
D. A. Sychev +6 more
doaj +1 more source
COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
Рациональная фармакотерапия в кардиологии, 2015 Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed ...
V. A. Sulimov +2 more
doaj +1 more source
The problem of choosing an anticoagulant for stroke prevention in patients with atrial fibrillation
Медицинский совет, 2014 The article is a literature review on the problem of thromboembolic complications in non-valvular atrial fibrillation, the peculiarities of anticoagulant therapy and challenges associated with the selection of drugs for stroke prevention.
EL Dolgova, IM Sokolov, YG Schwarz
doaj +1 more source
The main causes and current principles of prevention of cardioembolic stroke
Медицинский совет, 2015 Cardiocerebral embolism is responsible for the development of 30-40% of ischemic stroke events. [1-3] Apart from its high incidence, cardioembolic stroke (CEI) is often associated with significant residual impairment of motor, speech and coordination ...
A. V. Fonyakin, L. A. Geraskina
doaj +1 more source
Медицинский совет, 2016 Применение пероральных антикоагулянтов у пациентов в пожилом возрасте представляет серьезную проблему для клиницистов. У лиц с фибрилляцией предсердий (ФП) возраст старше 70 лет является фактором, существенно повышающим риск тромбоэмболических событий, и
doaj +1 more source
[Corticotropin-producing pheochromocytoma in multiple endocrine neoplasia type 1]. [PDF]
Probl Endokrinol (Mosk), 2023 Rebrova DV +12 more
europepmc +1 more source
Евразийский Кардиологический Журнал, 2020 Исследование реальной клинической практики на основе анализа записей в базе страховой компании Optum Clinformatics (“Optum”), опубликованное в начале марта в журнале Annals of Internal Medicine1 , показало преимущества апиксабана над ривароксабаном в ...
doaj
Main indications for peroral anticoagulants: how to choose an optimal drug
Качественная клиническая практика, 2018 Practical approaches to use of oral anticoagulants for prevention and treatment of thrombotic and thromboembolic complications in patients with atrial fibrillation, venous thromboembolism and coronary heart disease are considered.
I. S. Yavelov
doaj
Opyt primeneniya apiksabana pri fibrillyatsii predserdiy
КардиоСоматика, 2017 Цель. Внедрение в клиническую практику шкалы CHA2DS2-VASc и шкалы HAS-BLED обеспечивает индивидуальный подход в вопросах тромбопрофилактики у больных с фибрилляцией предсердий (ФП).
A. N Zakirova +6 more
doaj